Clinical Study

Rapastinel As An Added Therapy In Major Depressive Disorder

Posted Date: Sep 9, 2017

  • Investigator: Erik Nelson
  • Co-Investigator: Erik Nelson
  • Specialties: Depression, Psychiatry/Psychology
  • Type of Study: Drug

The purpose of this research study is to help understand how well experimental Rapastinel works to treat Major Depressive Disorder (MDD). “Experimental” means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Ad

Criteria:

To Be Considered For Enrollment Into The Study You Must: • Be Between 18 And 65 Years Of Age • Give Written Informed Consent • Have A Diagnosis Of Major Depressive Disorder • Be On An Ongoing Stable Dose Of A “Protocol Allowed” Adt That Is Not Full

Keywords:

Ketamine, Major Depressive Disorder, Depression, Null, Null

For More Information:

Jade Lord
513-558-4997
lordje@ucmail.uc.edu

  • Search Clinical Studies

  • Research in the News

    NIDA Director Nora Volkow to Speak on Opioid Crisis Nov. 27

    Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA), willbe the keynote speaker at a public symposium on tackling the opioid crisis onMonday, Nov. 27